Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05093322 · ClinicalTrials.gov registry record · Phase 1
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
A Phase 1 study, sponsored by Hutchmed.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT05093322 is a Phase 1 study that has completed, run by Hutchmed. The registered enrollment target is 13 participants.
The verdict
NCT05093322, a Phase 1 study, has completed, sponsored by Hutchmed.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of surufatinib, thereby identifying the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of surufatinib administered in combination with gemcitabine in pediatric patients with recurrent or refractory solid tumors or lymphoma. The study will be conducted in 2 parts.
Interventions
- DRUG Surufatinib in combination with Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-11-30 |
| Est. Completion | 2023-04-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05093322
The ClinicalTrials.gov registry entry for NCT05093322 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hutchmed, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Surufatinib in combination with Gemcitabine is the first listed.
NCT05093322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05093322 about?
NCT05093322 is a clinical study titled "A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors". The purpose of this study is to evaluate the safety and tolerability of surufatinib, thereby identifying the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of surufatinib administered in combination with gemcitabine in pediatric patients with recurrent or refractory solid tumors...
What is the current status of trial NCT05093322?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2021-11-30. Estimated completion is 2023-04-25.
What interventions are being tested in trial NCT05093322?
The interventions under investigation include: Surufatinib in combination with Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT05093322?
This trial is sponsored by Hutchmed, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.